Darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome.

⁽¹⁾ Mt Sinai School of Medicine, New York, NY;

⁽²⁾ UCLA Medical School-Hemat & Onc, Los Angeles, CA;

⁽³⁾ US Oncology-Hematology/Oncology Associates of South Texas, San Antonio, TX;

⁽⁴⁾ South Carolina Oncology Associates, Columbia, SC;

⁽⁵⁾ Amgen Inc., Thousand Oaks, CA.